Incidence of Bleomycin-Induced Hyperpigmentation in Patients Undergoing Sclerotherapy for Low-Flow Vascular Malformations
Open Access
- 17 February 2026
- journal article
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (5) , 108588
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Flagellate Erythema Induced by Bleomycin as a Sclerosant Agent in the Treatment of Venous MalformationDermatitis®, 2025
- Efficacy and safety of sclerosants in the treatment of venous malformations: A network meta-analysis of randomized controlled trialsChinese Journal of Plastic and Reconstructive Surgery, 2022
- Cutaneous hyperpigmentation following bleomycin sclerotherapy for vascular malformationsPediatric Dermatology, 2021
- Hyperpigmentation after Foamed Bleomycin Sclerotherapy for Vascular MalformationsJournal of Vascular and Interventional Radiology, 2019
- Short‐term side effects and patient‐reported outcomes of bleomycin sclerotherapy in vascular malformationsPediatric Blood & Cancer, 2018
- Bleomycin‐induced flagellate erythema after venous malformation sclerosis—Case report and brief reviewPediatric Dermatology, 2017
- Intralesional Bleomycin Injections for Vascular MalformationsPlastic and Reconstructive Surgery, 2016
- Flagellate Dermatitis as a Bleomycin-Specific Adverse Effect of Cytostatic TherapyAmerican Journal of Clinical Dermatology, 2011
- Bleomycin and the skinBritish Journal of Dermatology, 2006
- The role of redox-active metals in the mechanism of action of bleomycinChemico-Biological Interactions, 1990